This biweekly Oncology and Biopharma Regulatory Watch video recap highlights major regulatory approvals, label expansions, NDA acceptances, Phase 3 milestones, and expedited designations across lung, breast, colorectal, brain, and head and neck cancers in the US, EU, and Japan.
🎯 Watch Our Video Summary Capturing Oncology News from the Last Two Weeks
Dive deeper
🗓️ Explore more details and sources
- Week 16–22 February 2026
- Weeks 23 February–1 March 2026
📚 See the full Oncology archive on our research hub page.
Top Stories Covered in This Video
Chapters
0:00 Introduction
0:08 FIERCE-HN Phase 3 interim analysis completed
0:44 FDA approves monthly RYBREVANT FASPRO™ dosing
1:15 FDA accepts NDA for giredestrant in ESR1-mutated ER+ advanced breast cancer
1:54 EMA validates ENHERTU® Type II variation in early HER2+ breast cancer
2:23 EC approves new SC dosing regimens for RYBREVANT®
2:46 FDA Fast Track for SRN-101 in recurrent high-grade glioma
3:11 Japan approves Alpha DaRT® in unresectable H&N cancer
3:34 FDA grants full approval to BRAFTOVI® combination in 1L mCRC
4:07 How to reach us
Transcript
Welcome to the latest edition of Oncology Update, covering breakthroughs in the past two weeks. Brought to you by LucidQuest.
The global Phase 3 FIERCE-HN study in HPV-negative recurrent or metastatic head and neck squamous cell carcinoma completed its first interim analysis. Following an Independent Data Monitoring Committee recommendation and alignment with the FDA, the 20 milligrams per kilogram dose of ficlatuzumab was selected for combination with cetuximab. The registrational study plans to enroll between 410 and 500 patients, with overall survival as the primary endpoint, and enrollment is ongoing.
The FDA approved a once-monthly dosing schedule for RYBREVANT FASPRO in combination with lazertinib for first-line EGFR-mutated advanced non-small cell lung cancer. Transition to monthly dosing may occur as early as Week 5. Clinical data demonstrated comparable outcomes and safety relative to the bi-weekly subcutaneous regimen, while the subcutaneous formulation reduces administration time from hours to minutes.
The FDA accepted the NDA for giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer following endocrine therapy. The PDUFA date has been set for 18 December 2026. In the Phase 3 evERA study, the combination demonstrated a 44 percent reduction in the risk of progression or death in the intention-to-treat population and a 62 percent reduction in the ESR1-mutated subgroup compared with the comparator.
The EMA validated a Type II variation application for ENHERTU as monotherapy in patients with residual invasive HER2-positive early breast cancer following neoadjuvant treatment. Data from DESTINY-Breast05 showed a 53 percent reduction in invasive disease recurrence or death compared with T-DM1, signaling a potential shift in post-neoadjuvant treatment pending regulatory decision.
The European Commission approved new every-three-week and every-four-week subcutaneous dosing regimens for RYBREVANT across previously approved indications in advanced EGFR-mutated non-small cell lung cancer. Results from the PALOMA studies showed comparable safety to intravenous dosing and fewer administration-related reactions.
The FDA granted Fast Track designation to SRN-101, an AAV-based immuno-gene therapy platform, for the treatment of recurrent high-grade glioma. The designation is intended to facilitate development and expedite review. The program recently received IND clearance, enabling initiation of a first-in-human clinical trial.
Japan’s Ministry of Health, Labour and Welfare granted Shonin marketing approval to Alpha DaRT for the treatment of unresectable locally advanced or locally recurrent head and neck cancer. This marks the first approval outside Israel. A 66-patient post-marketing surveillance study is planned across five Japanese centers.
The FDA converted the accelerated approval of the BRAFTOVI combination to full approval for first-line treatment of BRAF V600E-mutant metastatic colorectal cancer based on Phase 3 BREAKWATER data. The study demonstrated a 51 percent reduction in the risk of death and a 47 percent reduction in the risk of progression or death compared with chemotherapy, establishing it as the only approved targeted regimen in this first-line molecular subset.
Stay ahead in Oncology and Biopharma Regulatory Watch research! Like, share, and subscribe for our updates. Visit www.lqventures.com or email us at info@lqventures.com for expert healthcare consulting. See you next time!
Why it matters
- Multiple FDA regulatory actions—including full approvals, NDA acceptance, and Fast Track designation—underscore continued momentum in precision oncology and novel platforms. [2], [3], [6], [8]
- Breast cancer updates span both early and advanced ESR1-mutated settings, with potential standard-of-care implications pending final decisions. [3], [4]
- EGFR-mutated NSCLC sees continued optimization of subcutaneous dosing strategies across US and EU markets. [2], [5]
- Japan’s approval of Alpha DaRT® highlights international expansion of device-based radiotherapeutic platforms. [7]
- Several updates represent process milestones (validation, interim analysis, expedited designation), with ultimate impact dependent on final regulatory outcomes and labeling. [1], [4], [6]
🗓️ Explore more details and sources
- Week 16–22 February 2026
- Weeks 23 February–1 March 2026
📚 See the full Oncology archive on our research hub page.
FAQ
What does completion of the first interim analysis in FIERCE-HN indicate?
It reflects IDMC review and dose selection for the combination arm, with the study continuing toward its overall survival endpoint. [1]
What is the significance of monthly SC dosing approval for RYBREVANT FASPRO™?
It simplifies administration while maintaining comparable efficacy and safety to the previously approved schedule. [2]
What is the timeline for giredestrant’s regulatory review?
The FDA set a PDUFA target action date of 18 Dec 2026 following NDA acceptance. [3]
Does EMA validation mean ENHERTU® is approved in this new setting?
No. Validation confirms the application is under review; approval depends on final EMA and EC decisions. [4]
What does Fast Track designation provide for SRN-101?
It allows more frequent FDA interaction and potential for expedited review pathways. [6]
What distinguishes the BRAFTOVI® combination approval?
It is now the only fully approved targeted regimen in first-line BRAF V600E-mutant metastatic colorectal cancer. [8]
Entities / Keywords
Ficlatuzumab (AVEO Oncology, LG Chem), FIERCE-HN, HPV-negative, recurrent/metastatic HNSCC, cetuximab, Phase 3, overall survival
RYBREVANT FASPRO™ (amivantamab + hyaluronidase-lpuj, Johnson & Johnson), LAZCLUZE® (lazertinib), EGFR-mutated NSCLC, monthly dosing, subcutaneous formulation
Giredestrant (Roche), everolimus, ER-positive, HER2-negative, ESR1-mutated, advanced breast cancer, evERA Phase 3, NDA, PDUFA 18 Dec 2026
ENHERTU® (trastuzumab deruxtecan, Daiichi Sankyo/AstraZeneca), HER2-positive early breast cancer, post-neoadjuvant, DESTINY-Breast05, invasive disease-free survival, Type II variation
RYBREVANT® (amivantamab), European Commission approval, Q3W/Q4W dosing, PALOMA studies, advanced EGFR-mutated NSCLC
SRN-101 (Siren Biotechnology), AAV-based immuno-gene therapy, recurrent high-grade glioma, Fast Track designation, IND clearance
Alpha DaRT® (Alpha Tau Medical), alpha radiation therapy, MHLW Shonin approval, unresectable head and neck cancer, post-market surveillance
BRAFTOVI® (encorafenib, Pfizer), cetuximab, BRAF V600E, metastatic colorectal cancer, BREAKWATER Phase 3, full FDA approval
